{"authors": [["Gupta", "Amit", "A", "Signalling and Cancer Metabolism Team, Division of Cancer Biology, The Institute of Cancer Research, London, UK."], ["Anjomani-Virmouni", "Sara", "S", "Signalling and Cancer Metabolism Team, Division of Cancer Biology, The Institute of Cancer Research, London, UK."], ["Koundouros", "Nikos", "N", "Signalling and Cancer Metabolism Team, Division of Cancer Biology, The Institute of Cancer Research, London, UK."], ["Poulogiannis", "George", "G", "Signalling and Cancer Metabolism Team, Division of Cancer Biology, The Institute of Cancer Research, London, UK."]], "date": "2017-05-19", "id": "29209642", "text": "Cancer and Parkinson disease (PD) derive from distinct alterations in cellular processes, yet there are pathogenic mutations that are unequivocally linked to both diseases. Here we expand on our recent findings that loss of parkin RBR E3 ubiquitin protein ligase (PRKN, best known as PARK2)-which is genetically linked to PD-promotes cancer progression via redox-mediated inactivation of phosphatase and tensin homolog (PTEN) by S-nitrosylation.", "doi": "10.1080/23723556.2017.1329692", "title": "PARK2 loss promotes cancer progression via redox-mediated inactivation of PTEN.", "journal": ["Molecular & cellular oncology", "Mol Cell Oncol"]}